Oxford Biomedica PLC

Earnings Release • May 16, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8260E

Oxford Biomedica PLC

16 May 2013

Oxford BioMedica Interim Management Statement

Oxford, UK - 16 May 2013: Oxford BioMedica ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 January to 15 May 2013.

OPERATIONAL HIGHLIGHTS

LentiVector® platform manufacturing

·      New manufacturing collaboration with Novartis expected to generate between £2.5 million to £4 million of income over the next 12 months

Ocular product development

·      Positive DSMB review of first three patient cohorts (n=12) in ongoing StarGen™ Phase I/IIa trial in April

·      UshStat® video selected to showcase theme of "Life-changing Research" at 2013 ARVO annual meeting

5T4 tumour antigen platform industry collaborations

·      First patient treated with TroVax® in Phase II mesothelioma study led by Velindre Cancer Centre, Wales

Targeted antibody therapy for cancer partnered with Pfizer

·      Multiple presentations of the 5T4 antibody drug conjugate (ADC) programme by Pfizer at key conferences:

̶    American Association for Cancer Research (AACR) annual meeting in April 2013

̶    The Ninth Annual PEGS, the essential protein & antibody engineering summit, in April 2013

FINANCIAL REVIEW

Oxford BioMedica's net cash1 balance at 31 December 2012, as stated in the annual report, was £14.1 million (audited).  At 30 April 2013, the Company had a net cash1 balance of £9.2 million (unaudited). Including income from the recently announced Novartis collaboration, the Company now has sufficient cash1 resources to fund operations into Q2 2014.

1.     Cash, cash equivalents and available for sale investments

OUTLOOK

Oxford BioMedica remains focused on completing the RetinoStat® Phase I study, generating further income from manufacturing, alliances and intellectual property, as well as initiating pre-clinical development of the next generation of ocular product opportunities.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "We have made a strong start to 2013 having secured a revenue-generating lentiviral vector manufacturing alliance.  We believe this not only validates our manufacturing capabilities, but is also a key step towards turning Oxford BioMedica into a company that is financially self-sustaining.  Having extended our financial resources into Q2 2014, we look forward to opportunities ahead and remain confident in our ability to deliver our strategic goals."

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: +44 (0)1865 783 000
Media Enquiries: Mary Clark/Sarah Macleod/Claire Dickinson M:Communications	Tel: +44 (0)20 7920 2360

Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IMSGGUPGAUPWGQA